Drug Patent Watch
JUNE 18, 2021
Annual Drug Patent Expirations for CLARINEX Clarinex is a drug marketed by Merck Sharp Dohme and is included in five NDAs. It is available from two suppliers. There are four…. The post New patent expiration for Merck Sharp drug CLARINEX appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 30, 2021
In line with the political objectives of the EU Green Deal, the program’s main goal is to fight climate change by establishing carbon farming practices at farmers’ level with benefits for the entire agricultural value chain / Program kicks off with over 25 farmers across seven countries in the EU and beyond: France, Spain, Belgium, Denmark, Germany, United Kingdom and Ukraine.
Drug Channels
JUNE 27, 2021
Happy 245th birthday, America! As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing. P.S.
Pharmaceutical Development Group
JUNE 17, 2021
After the FDA 510 k submissions, there is a lengthy review process there that is being performed by the team. Also, getting the certification is not a very easy task. For this reason, a brief checklist is here that are needed to be considered so that the submission and certification procedure will get more hassle-free. 1. Incomplete description When the company is applying for the FDA 510 k submissions , they need to ensure that they have provided a complete description for the product.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PerkinElmer
JUNE 14, 2021
The speed at which researchers developed effective vaccines to prevent the spread of COVID-19 required unprecedented international cooperation on a scale never seen before. Rollout of approved vaccines is underway in many countries across the globe, giving people hope that the end to the pandemic is finally in sight. Meanwhile, researchers are continuing to investigate possible treatments for patients suffering with the disease.
The Connected Lab
JUNE 2, 2021
Exploring how digital transformation will revolutionize process optimization and decision-making within the pharmaceutical industry Networked digital technologies and advanced automation are transforming pharmaceutical manufacturing , enabling efficiencies through real-time process optimization and faster decision-making. The impact of these technologies on drug development, production and logistics is so disruptive that many consider the sector to be entering a fourth industrial revolution, kno
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
The Pharma Data
JUNE 30, 2021
Approval based on Phase 2 CheckMate -142 trial results showing nearly two-thirds of patients responded to the Opdivo plus Yervoy combination with durable responses observed. Opdivo plus Yervoy is the first dual immunotherapy regimen approved in the European Union for colorectal cancer. Opdivo plus Yervoy- based combinations now indicated in the European Union for five different advanced cancer types: mesothelioma, non-small cell lung cancer, melanoma, renal cell carcinoma and colorectal cancer.
Drug Channels
JUNE 15, 2021
Drug Channels Institute’s latest review of contract pharmacies in the 340B Drug Pricing Program reveals that an astonishing 30,000 pharmacy locations—half of the entire U.S. pharmacy industry—now act as contract pharmacies for the hospitals and other healthcare providers that participate in the 340B program. Over the past 12 months, the number of pharmacies in the program has grown by more than 2,000 locations.
Olympian Clinical Research
JUNE 2, 2021
It’s estimated that over 18 million Americans suffer from atopic dermatitis, a chronic inflammatory skin condition that results in dry and itchy skin. While children make up almost half of those cases, atopic dermatitis (more commonly referred to as eczema) affects patients of all ages, genders, and ethnicities. Despite its prevalence, there’s still a lot that people don’t understand about atopic dermatitis, its symptoms, and the treatment methods available to patients who suffer from the condit
Crown Bioscience
JUNE 1, 2021
Dr Yujun Huang, Senior Director Immuno-Oncology at Crown Bioscience, answers the most popular questions from his recent organoids and immune cell co-cultures webinar , covering how to investigate tumor-antigen specific immune cell reactivity and optimal applications for a tumor organoid co-culture platform.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Practical Cheminformatics
JUNE 3, 2021
This is just a pointer to the fastpages blog post.
Drug Patent Watch
JUNE 7, 2021
Annual Drug Patent Expirations for TOVIAZ Toviaz is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent for Pfizer drug TOVIAZ appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 30, 2021
Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial to Test the Earlier Use of a CAR T-cell Therapy Against Standard of Care — — Study Met the Primary and Key Secondary Endpoints of Event-Free Survival and Objective Response Rate, Demonstrating a Highly Statistically and Clinically Significant Improvement Compared to Standard of Care — Kite, a Gilead Company (Nasdaq: GILD), today announced top-line results from the primary analysis of ZUMA-7, a
Drug Channels
JUNE 11, 2021
Today’s guest post comes from Jan Nielsen, Division President of AssistRx Patient Solutions. Jan provides five criteria that manufacturers can use when evaluating the capabilities of a Patient Solutions Provider (PSP), a.k.a. a hub vendor. To learn more, register for AssistRx's new, four-part webinar series: “Leading the Market in a Rapidly Changing Patient Solutions Landscape.”.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PerkinElmer
JUNE 7, 2021
Targeted cancer therapy has been a game changer in cancer treatment, significantly improving the survival and quality of life of many patients. Unlike chemotherapy, which acts on both cancer and normal cells, targeted therapy affects only the specific oncogenes, tumor suppressor genes, or pathways involved in tumor progression. Despite the success of targeted cancer therapy, the biggest hurdle to this treatment approach is the emergence of drug resistance, whereby some patients harbor subpopulat
Molecule Blog
JUNE 11, 2021
Imagine a world where patients directly fund researchers developing the next therapeutic breakthrough they need. One where drug development is collaborative, open, and decentralized — an open bazaar anyone with the right intentions can join. A system that could radically increase the diversity of treatments, and lower costs and time to market. The majority of promising early-stage therapeutic research lacks funding and access.
Drug Patent Watch
JUNE 6, 2021
This chart shows the drugs with the most patents in Russian Federation. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in Russian Federation? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are fourteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
JUNE 12, 2021
This chart shows the drugs with the most patents in Chile. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Chile? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 8, 2021
Annual Drug Patent Expirations for SOLOSEC Solosec is a drug marketed by Lupin and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent for LUPIN drug SOLOSEC appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 17, 2021
Annual Drug Patent Expirations for SOLOSEC Solosec is a drug marketed by Lupin and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent for LUPIN drug SOLOSEC appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 15, 2021
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are nineteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 14, 2021
Annual Drug Patent Expirations for SOTALOL+HYDROCHLORIDE Sotalol Hydrochloride is a drug marketed by Altathera Pharms Llc, Apotex, Beximco Pharms Usa, Epic Pharma Inc, Impax Pharms, Mylan, Oxford Pharms, Sun Pharm…. The post New patent for Altathera Pharms drug SOTALOL HYDROCHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2021
Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. There is one patent protecting this drug. This drug has twenty-three…. The post New patent for Beigene drug BRUKINSA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 14, 2021
Annual Drug Patent Expirations for DUAKLIR+PRESSAIR Duaklir Pressair is a drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Astrazeneca drug DUAKLIR PRESSAIR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 16, 2021
Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for Gilead Sciences drug VEKLURY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 14, 2021
Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-two patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 15, 2021
Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from three suppliers. There are twenty-five…. The post New patent for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 11, 2021
Annual Drug Patent Expirations for INJECTAFER Injectafer is a drug marketed by Am Regent and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Am Regent drug INJECTAFER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 14, 2021
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs…. The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 4, 2021
Annual Drug Patent Expirations for FERRIPROX Ferriprox is a drug marketed by Chiesi and is included in three NDAs. It is available from two suppliers. There are five patents protecting…. The post New patent for Chiesi drug FERRIPROX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 15, 2021
Annual Drug Patent Expirations for DEXYCU+KIT Dexycu Kit is a drug marketed by Eyepoint Pharms and is included in one NDA. There are five patents protecting this drug. This drug…. The post New patent for Eyepoint Pharms drug DEXYCU KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 15, 2021
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from three suppliers. There are twenty-one…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
98 
Let's personalize your content